Johnson & Johnson stock (NYSE: JNJ) is starting the week at the center of two storylines that often tug the share price in opposite directions: accelerating momentum in oncology and a stubborn, headline‑driven litigation risk.
On Monday, December 15, 2025, JNJ shares traded around the $214 level, brushing the upper end of their recent trading range and extending a rally that has put the healthcare bellwether sharply higher on the year. [1]
What’s moving JNJ today isn’t a single earnings surprise. Instead, it’s a high‑impact regulatory catalyst—a newly granted FDA priority voucher tied to a multiple myeloma regimen—arriving the same day investors are also digesting a fresh talc verdict that underscores why the legal overhang hasn’t disappeared. [2]
Below is a detailed look at the latest news, Wall Street forecasts, and key bull/bear factors shaping the Johnson & Johnson stock outlook as 2025 heads toward the finish line.
Why Johnson & Johnson stock is in focus on Dec. 15, 2025
1) FDA grants a “national priority voucher” to JNJ’s blood cancer treatment
The biggest positive headline for Johnson & Johnson stock today is regulatory: the U.S. Food and Drug Administration granted a national priority voucher to J&J’s Tecvayli in combination with Darzalex for multiple myeloma, after the regimen showed a significant improvement over standard of care in a late‑stage trial, according to Reuters. [3]
The voucher matters because it ties into a new FDA initiative that can compress review timelines dramatically:
- Reuters reports the program was launched in June 2025. [4]
- It can cut the review timeline to one to two months, versus the usual 10–12 months. [5]
- The Tecvayli + Darzalex award brings the total number of products receiving an award under the program to 16 this year, per the same report. [6]
For investors, the key takeaway is not just speed—it’s optionality. Faster review windows can pull forward revenue, reduce uncertainty, and give Johnson & Johnson more flexibility in sequencing label expansions across its oncology franchise.
2) The underlying clinical story: MajesTEC‑3 data strengthens the “next leg” narrative
This voucher didn’t come out of nowhere. In early December, Johnson & Johnson published detailed data from the Phase 3 MajesTEC‑3 study on the Tecvayli (teclistamab) + Darzalex Faspro (daratumumab) combination.
In its December 9 press release, J&J said the regimen demonstrated:
- An 83% reduction in the risk of disease progression or death vs standard regimens at nearly three years of follow‑up (hazard ratio 0.17). [7]
- Overall survival favoring the combination (OS hazard ratio 0.46) and OS rates of 83.3% vs 65.0% at three years. [8]
- The data were presented at the American Society of Hematology (ASH) Annual Meeting with simultaneous publication in The New England Journal of Medicine, per J&J. [9]
- J&J also noted it submitted a supplemental Biologics License Application (sBLA) and that the FDA granted Breakthrough Therapy Designation for the combination regimen. [10]
In plain English: investors are watching Johnson & Johnson attempt to move a powerful therapy earlier in the treatment journey, where patient pools are larger and commercial opportunities can be meaningfully bigger.
The risk headline: $40 million talc verdict keeps the legal cloud alive
While the FDA story supports the bull case, Johnson & Johnson stock is also contending with litigation news that can quickly swing sentiment.
Reuters reported on December 15 that a California jury awarded $40 million to two women who alleged J&J baby powder caused their ovarian cancer:
- $18 million to Monica Kent and $22 million to Deborah Schultz and her husband, Reuters said. [11]
- Reuters also reported J&J faces lawsuits from more than 67,000 plaintiffs in talc‑related claims. [12]
- J&J said it plans to appeal the verdict. [13]
- Importantly for investors tracking potential “global resolution,” Reuters noted J&J’s bankruptcy strategy has been rejected three times, most recently in April, and that these were the first trials since the latest Chapter 11 attempt was dismissed. [14]
The Associated Press added further context that J&J stopped selling talc‑based powder worldwide in 2023, and described the broader litigation backdrop, including the judge’s earlier rejection of a proposed $9 billion settlement plan. [15]
Why this matters for JNJ stock: even though Johnson & Johnson has the scale and cash generation to absorb legal costs over time, talc headlines can create periodic volatility—especially when the stock is trading near the top end of its recent range.
Wall Street forecasts on Dec. 15: price targets rise, but upside looks more “selective” after the rally
A notable theme in today’s JNJ coverage is that analysts are lifting price targets, yet the average target still sits close to—or even below—where the stock trades now.
Bank of America raises target to $220, keeps Neutral
A GuruFocus recap published December 15 said BofA Securities maintained a Neutral rating but raised its price target to $220 (from $204). [16]
A broader wave of upward revisions in early-to-mid December
The same GuruFocus update listed several other notable target moves in December, including:
- RBC Capital: Outperform, target raised to $230 (from $209) [17]
- Citigroup: Buy, target raised to $232 (from $215) [18]
- Guggenheim: Buy, target raised to $227 (from $206) [19]
- Morgan Stanley: Equal‑Weight, target raised to $197 (from $190) [20]
- Barclays: Equal‑Weight, target raised to $197 (from $176) [21]
Consensus targets suggest JNJ is closer to “fair value” than “deep discount”
- GuruFocus reported an average one‑year target of $206.70 (high $240, low $170) based on 27 analysts, and characterized the average recommendation as roughly “Outperform.” [22]
- MarketBeat, in its December 15 write‑up, similarly cited an average price target of $208.35 and described the consensus rating as “Moderate Buy.” [23]
- MarketScreener’s consensus snapshot also showed an average target price around $207, with a consensus label of OUTPERFORM. [24]
The implication for investors: after a strong run, Johnson & Johnson stock appears to be shifting from a “re‑rating story” to a delivery story—where the next meaningful leg higher likely requires new catalysts (approvals, label expansions, clearer post‑spin strategy) rather than multiple expansion alone.
A fresh piece of Dec. 15 analysis: Wolfe Research ranks JNJ as a top pharma stock to watch
Another notable Dec. 15 datapoint for the JNJ stock narrative: an Investing.com report citing Wolfe Research ranked Johnson & Johnson as the top pharmaceutical name in its list of industry leaders.
According to that report, Wolfe’s constructive view is tied to:
- New products and label expansions [25]
- A “robust” icotrokinra launch creating a new growth avenue [26]
- Tremfya expansion into inflammatory bowel disease indications [27]
- Upcoming J‑codes for Inlexzo and Imaavy as potential sales inflection drivers [28]
But Wolfe also flagged several headwinds investors should not ignore:
- An “unfavorable patient mix” tied to the 340B Drug Pricing Program [29]
- Ongoing talc litigation concerns as the company returns to the tort system [30]
- Slowing Darzalex growth outside the United States [31]
This “two‑handed” framing—strong product execution, but real policy/legal constraints—is increasingly the way major investors are modeling JNJ into 2026.
Fundamentals check: what J&J has already guided for—and what’s next
Even when the news cycle is dominated by FDA headlines and court verdicts, Johnson & Johnson stock ultimately tracks the company’s ability to deliver steady revenue, resilient margins, and credible innovation.
Q3 2025 results: higher sales outlook, reaffirmed EPS midpoint
In its Q3 2025 results announcement, Johnson & Johnson reported:
- Q3 2025 sales of $24.0 billion [32]
- Q3 adjusted EPS of $2.80 [33]
- A raised full‑year 2025 sales outlook (Reuters reported a range of $93.5B–$93.9B) [34]
- The company reaffirmed full‑year adjusted EPS guidance at $10.85 at the midpoint, per J&J’s release [35]
Strategic reshaping continues: orthopedics spin planned
Reuters reported in October that J&J plans to spin off its orthopedics business into a standalone entity named DePuy Synthes within 18 to 24 months, as part of an effort to focus on higher‑growth areas. [36]
For Johnson & Johnson stockholders, this matters because the company is effectively trying to sharpen the investment case around:
- A higher‑innovation Innovative Medicine engine
- A scale MedTech platform
- And a simpler story after major portfolio moves (including the Kenvue consumer separation)
GuruFocus also summarized J&J’s post‑consumer structure as two divisions—innovative medicine and medtech—after the consumer business was divested into Kenvue in 2023. [37]
Another near‑term catalyst: AKEEGA approval expands the oncology footprint
Although not dated exactly Dec. 15, it’s part of the immediate “current outlook” investors are weighing this week: the FDA’s recent approval of Akeega (niraparib + abiraterone acetate) with prednisone for certain prostate cancer patients.
The FDA said on December 12, 2025 it approved Akeega with prednisone for adults with BRCA2‑mutated metastatic castration‑sensitive prostate cancer (mCSPC), as determined by an FDA‑approved test. [38]
This fits the broader market narrative that J&J is attempting to offset looming competitive and patent‑cycle pressures by stacking oncology and specialty medicine growth drivers—a theme also reflected in Wolfe’s “top pharma” view. [39]
Johnson & Johnson dividend: why income investors still keep JNJ on watchlists
A big reason Johnson & Johnson stock remains a core holding for many long‑term portfolios is its dividend profile.
- Johnson & Johnson announced a $1.30 quarterly dividend for Q4 2025, payable December 9, 2025, with a record and ex‑dividend date of November 25, 2025. [40]
- Earlier in 2025, J&J said it marked its 63rd consecutive year of dividend increases, raising the quarterly dividend from $1.24 to $1.30 (a 4.8% increase). [41]
For investors focused on stability, that dividend track record can cushion periods when litigation headlines dominate the tape.
JNJ stock price snapshot (Dec. 15, 2025): near highs, expectations rising
As of Monday’s session, multiple market data sources showed JNJ trading near the top end of its 52‑week range:
- Investing.com displayed a daily range roughly $209 to $214, with the upper end around $214.38. [42]
- MarketScreener showed JNJ around $213.96 midday (U.S. Eastern), with a year‑to‑date change near +48%. [43]
That positioning matters because it raises the bar for what “good news” must look like. When a stock is already priced near the high end of recent trading, incremental positives (like another price target bump) can have less impact than a truly material catalyst (like a meaningful accelerated approval timeline, a major settlement, or a step‑change in guidance).
What to watch next for Johnson & Johnson stock
Going into 2026, the JNJ stock debate is likely to hinge on whether the company can keep delivering incremental growth catalysts faster than the market discounts legal and policy friction.
Key items on watchlists:
- Regulatory speed and label expansion cadence: The FDA voucher for Tecvayli + Darzalex is a concrete sign that review timelines can be shortened. [44]
- Commercial execution and mix: Wolfe Research flagged 340B patient mix and international Darzalex growth as areas investors are monitoring. [45]
- Talc litigation path: With jury verdicts back in focus and bankruptcy routes rejected, the market will watch appeals, trial pacing, and any credible path toward broad resolution. [46]
- Analyst expectations vs. price: Targets have risen into the $220–$240 zone at the high end, but consensus averages remain closer to the low $200s—suggesting the stock may need fresh upside catalysts to justify another leg higher. [47]
Bottom line: JNJ has momentum—but it’s now a “prove it” phase
Johnson & Johnson stock enters the final stretch of 2025 with strong momentum, supported by a pipeline and regulatory backdrop that is producing tangible wins—most notably the FDA national priority voucher tied to Tecvayli + Darzalex in multiple myeloma. [48]
At the same time, the day’s other headline—the $40 million talc verdict—is a reminder that JNJ’s legal risk isn’t theoretical, and it can still inject volatility into the share price even when fundamentals look steady. [49]
References
1. www.investing.com, 2. www.reuters.com, 3. www.reuters.com, 4. www.reuters.com, 5. www.reuters.com, 6. www.reuters.com, 7. www.jnj.com, 8. www.jnj.com, 9. www.jnj.com, 10. www.jnj.com, 11. www.reuters.com, 12. www.reuters.com, 13. www.reuters.com, 14. www.reuters.com, 15. apnews.com, 16. www.gurufocus.com, 17. www.gurufocus.com, 18. www.gurufocus.com, 19. www.gurufocus.com, 20. www.gurufocus.com, 21. www.gurufocus.com, 22. www.gurufocus.com, 23. www.marketbeat.com, 24. www.marketscreener.com, 25. www.investing.com, 26. www.investing.com, 27. www.investing.com, 28. www.investing.com, 29. www.investing.com, 30. www.investing.com, 31. www.investing.com, 32. www.investor.jnj.com, 33. www.investor.jnj.com, 34. www.reuters.com, 35. www.investor.jnj.com, 36. www.reuters.com, 37. www.gurufocus.com, 38. www.fda.gov, 39. www.investing.com, 40. www.investor.jnj.com, 41. www.jnj.com, 42. www.investing.com, 43. www.marketscreener.com, 44. www.reuters.com, 45. www.investing.com, 46. www.reuters.com, 47. www.gurufocus.com, 48. www.reuters.com, 49. www.reuters.com
